« Return to News | Drug Sponsors

Vivus board appoints new chairman, CEO

Wednesday, July 24, 2013 03:00 PM

Biopharmaceutical company Vivus’ board of directors has appointed Michael Astrue chairman and Anthony Zook chief executive officer.

Astrue previously was chief executive officer of Transkaryotic Therapies, chairman of the Massachusetts Biotechnology Council and commissioner of Social Security. Zook previously was executive vice president, global commercial operations for AstraZeneca and president of Medimmune.

Vivus sells obesity drug Qsymia (phentermine and topiramate extended-release) capsules CIV in the U.S.

"We intend to move quickly on our four main goals: expand use of Qsymia through targeted patient and physician education, find the right partner for Qsymia, quickly create a pathway for approval in Europe and eliminate expenses not essential to expanding use of Qsymia,” said Astrue.

"Obesity is a growing disaster for Americans,” said Zook. “Aside from its human costs, it creates economic costs due to associated comorbidities such as diabetes, strokes, heart attacks and depression. Our mission is to ensure at-risk patients and their physicians know about Qsymia and have the information necessary to determine whether Qsymia can help address this condition."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.